Algernon Pharmaceuticals Inc. (CSE:AGN)

Acelyrin Balance Sheet

Financials in millions CAD. Fiscal year is September - August.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	May 31, 2025	Aug 31, 2024	Aug 31, 2023	Aug 31, 2022	Aug 31, 2021	Aug 31, 2020
Cash & Equivalents	0.09	0.6	0.13	1.41	2.41	6.12
Cash & Short-Term Investments	0.09	0.6	0.13	1.41	2.41	6.12
Cash Growth	-85.53%	376.63%	-91.12%	-41.58%	-60.61%	2845.66%
Other Receivables	0.01	0.02	0.1	0.67	2.29	1.23
Receivables	0.01	0.02	0.1	0.67	2.29	1.23
Prepaid Expenses	0.13	0.13	0.12	0.75	0.2	0.39
Total Current Assets	0.23	0.74	0.34	2.83	4.91	7.74
Other Intangible Assets	4.21	3.18	3.8	5.26	5.17	5.03
Other Long-Term Assets	0.03	0.03	0.06	0.06	0.06	0.06
Total Assets	4.88	3.94	4.19	8.14	10.14	12.82
Accounts Payable	2.07	1.75	2.7	2.24	1.02	0.61
Accrued Expenses	0.12	0.02	0.02	0.27	0	-
Total Current Liabilities	2.87	1.78	2.72	2.52	1.02	0.61
Total Liabilities	3.14	1.78	2.72	2.52	1.02	0.61
Common Stock	30.17	29.56	28.15	27.12	25.85	21.34
Retained Earnings	-30.45	-30.76	-30.79	-25.19	-23.55	-17.46
Comprehensive Income & Other	2.02	3.37	4.12	3.7	6.81	8.34
Shareholders' Equity	1.74	2.17	1.47	5.62	9.12	12.22
Total Liabilities & Equity	4.88	3.94	4.19	8.14	10.14	12.82
Net Cash (Debt)	0.09	0.6	0.13	1.41	2.41	6.12
Net Cash Growth	-85.53%	376.63%	-91.12%	-41.58%	-60.61%	2845.66%
Net Cash Per Share	0.00	0.03	0.01	0.20	0.39	1.74
Filing Date Shares Outstanding	34.26	27.3	19.51	9.54	6.7	5.7
Total Common Shares Outstanding	34.26	27.3	15.78	9.43	6.7	5.53
Working Capital	-2.64	-1.04	-2.38	0.31	3.89	7.13
Book Value Per Share	0.05	0.08	0.09	0.60	1.36	2.21
Tangible Book Value	-2.88	-1.01	-2.32	0.37	3.94	7.19
Tangible Book Value Per Share	-0.08	-0.04	-0.15	0.04	0.59	1.30

Updated Jan 29, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.